image credit- shutterstock
Thermo Fisher Scientific Inc. has announced an expansion of their strategic partnership with Sanofi to enable additional US drug product manufacturing.
Under the agreement, Thermo Fisher will acquire Sanofi’s steriles manufacturing site in Ridgefield, New Jersey, US and will continue to manufacture a portfolio of therapies for Sanofi.
In addition, Thermo Fisher will expand use of the site to meet the growing demand from pharma and biotech customers for US manufacturing capacity. The Ridgefield site is a state-of-the-art sterile fill-finish and packaging facility with a world-class team of more than 200 employees who will join Thermo Fisher following the completion of the transaction.
The transaction is expected to be completed in the second half of 2025, subject to customary closing conditions. Upon completion of the transaction, Sanofi’s Ridgefield facility will become part of Thermo Fisher's pharma services business within its Laboratory Products and Biopharma Services segment.
Thermo Fisher operates a leading global sterile fill-finish manufacturing network, which currently includes U.S. sites in Greenville, North Carolina and Plainville, Massachusetts. These sites are integral to the company’s Accelerator™ Drug Development 360° CDMO and CRO solutions, transforming the pharmaceutical value chain for emerging biotech and biopharma companies to speed life-changing medicines to patients.
“Sanofi’s Ridgefield site will strengthen our U.S. manufacturing capabilities, enabling us to better support our pharmaceutical and biotech customers with the critical production capacity needed for essential medicines,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher. “We will also expand and further strengthen our long-standing partnership with Sanofi, while investing to bring additional capacity and enhanced capabilities at this site. We look forward to welcoming all Ridgefield employees to Thermo Fisher later this year.”
